Seeking Alpha

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make...

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make sense if the chatter is true that the company is lined up as an acquisition target by Big Pharma, according to Michael Morhamus. Unfazed by the stock's 510% YTD return on the promise of its breast cancer treatment, he notes that institutional money avoids "highly promoted" stocks like GALE.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)